Claims
- 1. A method for treating brain cancer, breast cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, or colorectal cancer, said method comprising administering to a patient in need of such treatment a pharmaceutically-effective amount of a compound of formula (I): whereinW is OR1, NR2OR1, NRARB, NR2NRARB, or NR2(CH2)2-4 NRARB; R1 is H, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, phenyl, (phenyl)C1-4 alkyl, (phenyl)C3-4 alkenyl, (phenyl)C3-4 alkynyl, (C3-8 cycloalkyl)-C1-4 alkyl, (C3-8 cycloalkyl)C3-4 alkenyl, (C3-8 cycloalkyl)C3-4 alkynyl, C3-8 heterocyclic radical, (C3-8 heterocyclic radical)C1-4 alkyl, (C3-8 heterocyclic radical)C3-4 alkenyl, (C3-8 heterocyclic radical)C3-4 alkynyl or (CH2)2-4NRARB; R2 is H, phenyl, C1-4 alkyl, C3-4 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, or (C3-8 cycloalkyl)C1-4 alkyl; RA is H, C3-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, phenyl, (C3-8 cycloalkyl)C1-4 alkyl, (C3-8 cycloalkyl)C3-4 alkenyl, (C3-8 cycloalkyl)C3-4 alkynyl, C3-8 heterocyclic radical, (C3-8 heterocyclic radical)C1-4 alkyl, (aminosulfonyl)phenyl, [(aminosulfonyl)phenyl]C1-4 alkyl, (aminosulfonyl)C1-6 alkyl, (aminosulfonyl)C3-6 (aminosulfonyl)C3-4 cycloalkyl, or [(aminosulfonyl)C3-6 cycloalkyl]C1 alkyl; RB is H, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, or C6-8 aryl; R3 is H, F, Cl, Br, or NO2; R4 is H or F; R5 is H, methyl or Cl; R6 is H, C1-4 alkyl, hydroxyopyl, (CH2)2-4(NRCRD), phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl or CH2Ar, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl; R7 is H, C1-4 alkyl, hydroxyethyl, hydroxypropyl, (CH2)2-4(NRCRD), phenyl, 2-pyridyl, 3-pridyl, 4-pyridyl, or CH2Ar′, where Ar′ is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl; each of RC and RD is independently selected from H, C1-6 alkyl, C3-4 alkenyl, C3-4 alkynyl, C1-6 cycloalkyl, C3-6 heterocyclic radical, and phenyl; NRCRD is also selected from the group consisting of morpholinyl, piperazinyl, pyrrolidinyl, and piperadinyl; wherein each hydrocarbon radical or heterocyclic radical above is optionally substituted with between 1 and 3 substituents independently selected from halo, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl , hydroxy, amino, (amino)sulfonyl, and NO2, wherein each substituent alkyl, cycloalkyl, alkenyl, alkynyl or phenyl is in turn optionally substituted with between 1 and 3 substituents independently selected from halo, C1-2 alkyl, hydroxy, amino, and NO2; or a phannaceutically-acceptable salt or C1-6 ester thereof.
- 2. A method for treating a viral infection, selected from the group consisting of HIV, hepatitis B virus, human papilloma virus, cytomegalovirus, and Epstein Barr virus, said method comprising administering to a patient in need of such treatment a pharmaceutically-effective amount of a compound of formula (I): whereinW is OR1, NR2OR1, NRARB, NR2NRARB, or NR2(CH2)2-4NRARB; R1 is H, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, phenyl, (phenyl)C1-4 alkyl, (phenyl)C3-4 alkenyl, phenyl)C3-4 alkynyl, (C3-8 cycloalkyl)-C1-4 alkyl, (C3-8 cycloalkyl)C3-4 alkenyl, (C3-8 acycloalkyl)C3-4 alkynyl, C3-8 heterocyclic radical, (C3-8 heterocyclic radical)C1-4 alkyl, (C3-8 heterocyclic radical)C3-4 alkenyl, (C3-8 heterocyclic radical)C3-4 alkynyl or (CH2)2-4NRARB; R2 is H, phenyl, C1-4 alkyl, C3-4 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, or (C3-8 cycloalkyl)-C1-4 alkyl; RA is H, C3-8 alkyl, C3-8 alkenyl, C3-8 cycloakyl, phenyl (C3-8 cycloalkyl)C1-4 alkyl, (C3-8 cycloalkyl)C3-4 alkenyl, (C3-8 cycloalkyl)C3-4 alkynyl, C3-8 heterocyclic radical, (C3-8 hererocyclic radical)C1-4 alkyl, (aminosulfonyl)phenyl, [(aminosulfonyl)phenyl]C1-4 alkyl, (aminosulfonyl)C1-6 alkyl, (aminosulfonyl)C3-6 cycloalkyl, or [(aminosulfonyl)C3-6 cycloalkyl]C1-4 alkyl; RB is H, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, or C6-8 aryl; R3 is H, F, Cl, Br, or NO2; R4 is H or F, R5 is H, methyl or Cl; R4 is H, C1-4 alkyl, hydroxyethyl, hydroxypropyl, (CH2)2-4(NRCRD), phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl or CH2Ar, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl; R7 is H, C1-4 alkyl, hydroxyethyl, hydroxypropyl, (CH2)2-4(NRCRD) phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or CH2Ar′, where Ar′ is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl; each of RC and RD independently selected from H, C1-6 alkyl, C3-4 alkenyl, C3-4 alkynyl, C3-6 cycloalkyl, C3-6 heterocyclic radical, and phenyl; NRCRD is also selected from the group consisting of morpholinyl, piperazinyl, pyrrolidinyl, and piperadinyl; wherein each hydrocarbon radical or heterocyclic radical above is optionally substituted with between 1 and 3 substituents independently selected from halo, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, hydroxy, amino, (amino)sulfonyl, and NO2, wherein each substituent alkyl, cycloalkyl, alkenyl, alkynyl or phenyl is in turn optionally substituted with between 1 and 3 substituents independently selected from halo, C1-2 alkyl, hydroxy, amino, and NO2; or a pharmaceutically-acceptable salt or C1-6 ester thereof.
- 3. A method of claim 2, wherein said viral infection is an infection of HIV.
Parent Case Info
This application is a Divisional application of U.S. Ser. No. 09/869,639 filed Jul. 2, 2001, issued as U.S. Pat. No. 6,440,966 on Aug. 27, 2002, which is a 371 application of PCT/US99/30435 filed Dec. 21, 1999, which claims the benefit of priority to U.S. provisional application Serial No. 60/115,874 filed Jan. 13, 1999 and U.S. provisional application Serial No. 60/122,422 filed Mar. 2, 1999.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5525625 |
Bridges et al. |
Jun 1996 |
A |
6310060 |
Barrett et al. |
Oct 2001 |
B1 |
Foreign Referenced Citations (2)
Number |
Date |
Country |
9837881 |
Mar 1998 |
WO |
WO 9901426 |
Jan 1999 |
WO |
Non-Patent Literature Citations (2)
Entry |
PCT International Search Report, PCT/US99/30435. |
A.N. Gaidukevich, et al., “Reactivity of Derivatives of Phenyl-Anthranilic Acid. IX. Acid-Base Properties of Sulfamoylic Derivatives of Phenyl-Anthranilic acid in mixed Solvent Dioxan-Water”, Organic Reactivity, 1990, vol. 27, pp 152-158. |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/115874 |
Jan 1999 |
US |
|
60/122422 |
Mar 1999 |
US |